Authors: Bekhit A.A., El-Agroudy E., Helmy A., Ibrahim T.M., Shavandi A., Bekhit A.E.-D.A.
Author Affiliations: Bekhit, A.A., Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt, Pharmacy Program, Allied Health Department, College of Health Sciences, University of Bahrain, P.O. Box 32038, Bahrain; El-Agroudy, E., Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt; Helmy, A., Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt; Ibrahim, T.M., Pharmaceutical Chemistry Department, Faculty of Pharmacy, Kafrelsheikh University, Kafr El-Sheikh, 33516, Egypt; Shavandi, A., Centre for Materials Science and Technology, University of Otago, Dunedin, New Zealand, Interfaculty School of Bioengineers, Université Libre de Bruxelles, Brussels, Belgium; Bekhit, A.E.-D.A., Department of Food Science, University of Otago, Dunedin, New Zealand
Publication Date: 2018
Leishmaniasis affects over 150 million people all over the world, especially in subtropical regions. Currently used antileishmanial synthesized drugs are associated with some drawbacks such as resistance and cytotoxicity, which hamper the chances of treatment. Furthermore, effective leishmanial vaccines are not well developed. Promising chemotherapy, either from natural or synthetic compounds, was or still is the most promising treatment. This review focuses on recent findings in drugs used for the treatment of leishmaniasis including; chemical and natural antileishmanial moieties, different potential targets, as well as various trials of vaccination development. Special emphasis has been paid to the mechanisms of the drugs, their safety and where possible, the structure-activity relationship to enable guided future drug discovery. © 2018 Elsevier Masson SAS
Eshan2020-11-28T18:20:18+00:00
